Lupus pathogenesis (WP5559)

Homo sapiens

Systemic lupus erythematosus (SLE) is an autoimmune disease in which the body’s immune system mistakenly attacks its own tissues. It can lead to lupus nephritis, where the kidneys become inflamed. This causes impaired kidney function and, in severe cases, kidney failure. Lupus has an incidence of around 5 per 100,000 person-years, and affects women much more frequently than men. The development of lupus nephritis involves a complex interplay among B cells, T cells, dendritic cells (DCs), and other immune components. Key pathogenic mechanisms include: 1. Overactive B cells produce excessive autoantibodies, leading to the formation of immune complexes that deposit in the kidneys. These deposits trigger complement activation and subsequent inflammation. 2. Autoreactive B cells present self-antigens to T cells, promoting persistent immune dysregulation and the release of pro-inflammatory cytokines. 3. Dendritic cells display abnormal recognition and presentation of self-antigens, which initiates and sustains autoimmune responses targeting renal tissues. 4. B cell differentiation into plasma cells is dysregulated, resulting in continuous production of nephritogenic autoantibodies. Understanding these immunopathogenic processes is critical for the development of targeted therapies aimed at preventing or reversing the progression of lupus nephritis. Inspired by Figure 2 in Su et al. (2024).

For a description of pathway objects, see the WikiPathways Legend.

Authors

Eric Weitz and Alex Pico

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Disease Ontology

lupus erythematosus lupus nephritis

Cell Type Ontology

T-helper 17 cell macrophage dendritic cell B cell T cell plasma cell

Participants

Label Type Compact URI Comment
Autoantibodies GeneProduct wikidata:Q785022
TLR4 GeneProduct ensembl:ENSG00000136869
TLR7 GeneProduct ensembl:ENSG00000196664
TLR9 GeneProduct ensembl:ENSG00000239732
BCR GeneProduct ensembl:ENSG00000186716
TNFSF13B GeneProduct ensembl:ENSG00000102524 'BAFF' in source
TNFRSF13C GeneProduct ensembl:ENSG00000159958 'BAFFR' in source
CD274 GeneProduct ensembl:ENSG00000120217 'PDL1' in source
CD40 GeneProduct ensembl:ENSG00000101017
ICOSLG GeneProduct ensembl:ENSG00000160223 'ICOSL' in source
CD86 GeneProduct ensembl:ENSG00000114013
CD80 GeneProduct ensembl:ENSG00000121594
CD40LG GeneProduct ensembl:ENSG00000102245 'CD40L' in source
PDCD1 GeneProduct ensembl:ENSG00000188389 'PD1' in source
CD28 GeneProduct ensembl:ENSG00000178562
ICOS GeneProduct ensembl:ENSG00000163600
IFNA2 GeneProduct ensembl:ENSG00000188379 'IFNA' in source
IL17A GeneProduct ensembl:ENSG00000112115 'IL17' in source
IL6 GeneProduct ensembl:ENSG00000136244

References

  1. Systemic lupus erythematosus: pathogenesis and targeted therapy. Su X, Yu H, Lei Q, Chen X, Tong Y, Zhang Z, et al. Mol Biomed. 2024 Oct 30;5(1):54. PubMed Europe PMC Scholia